Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Reversal of Neuromuscular Blockade

Interventions

DRUG: Sugammadex 2 mg/kg
DRUG: Sugammadex 4 mg/kg
DRUG: Sugammadex 16 mg/kg
DRUG: Neostigmine + Glycopyrrolate
DRUG: Rocuronium
DRUG: Vecuronium

Sponsor

Merck Sharp & Dohme LLC